Disc Medicine, Inc.
Disc Medicine, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Study of DISC-0974-201 in Participants With IBD and Anemia on October 15, 2026. There are 6 upcoming events on record.
Cash runway is approximately 34.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 | Study of DISC-0974-201 in Participants With IBD and Anemia | Trial Milestone | Phase 2 |
| December 11, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 15, 2027 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Trial Milestone | Phase 2 |
| May 15, 2027 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | Trial Milestone | Phase 1 |
| June 15, 2028 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP | Trial Milestone | Phase 2/Phase 3 |
Track IRON alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IRON in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.